US20050055071A1 - Method of treating erythematous papules - Google Patents

Method of treating erythematous papules Download PDF

Info

Publication number
US20050055071A1
US20050055071A1 US10/913,075 US91307504A US2005055071A1 US 20050055071 A1 US20050055071 A1 US 20050055071A1 US 91307504 A US91307504 A US 91307504A US 2005055071 A1 US2005055071 A1 US 2005055071A1
Authority
US
United States
Prior art keywords
light
dermal
skin
region
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/913,075
Inventor
Eric Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/913,075 priority Critical patent/US20050055071A1/en
Publication of US20050055071A1 publication Critical patent/US20050055071A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • A61B2018/0047Upper parts of the skin, e.g. skin peeling or treatment of wrinkles

Definitions

  • the present invention relates in general to laser treatment of dermatological imperfections.
  • the invention relates in particular to non-ablative laser treatment of erythematous papules such as acne and rosacea.
  • the present invention is directed to a method for treating erythematous papules as well as the skin between the papules.
  • Acne-prone skin is erythematous not only in areas of active acne, but also in areas where acne has previously occurred, or where it is about to occur.
  • acne lesions often have excess melanin pigment in the area where inflammation has caused deposition of excess epidermal melanin in the superficial dermis and in the area of the hair follicles.
  • the method of the present invention comprises irradiating the skin to be treated with light (electromagnetic radiation) having a wavelength selected such that it is preferentially absorbed in a dermal region of the skin including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below the melanocyte layer.
  • the light is delivered at a fluence sufficient that the preferential absorption thereof stimulates a wound healing response in the dermal region without causing a wound.
  • the wound healing response promotes growth of dermal collagen, and other extracellular matrix and inflammatory compounds, in the area surrounding the hair follicles.
  • This reorganization of dermal collagen affects the structure and function of sebaceous glands, altering their activity and reducing the incidence, severity and appearance of erythematous papules such as, but not limited to, rosacea, and both inflammatory and comedonal acne.
  • the light has a wavelength between about 525 and 550 nanometers (nm).
  • the light may be delivered in the form of pulses thereof or as a continuous beam swept or scanned over an area of skin being treated.
  • pulsed electromagnetic radiation having a wavelength of 532 nm, delivered by a frequency-doubled Nd:YAG laser was arranged to deliver a spot having a diameter of about 3 millimeters (mm).
  • the pulse duration was about 2.0 milliseconds (ms).
  • An average fluence of 7.5 Joules per square centimeter (J/cm 2 ) was used to treat 6 volunteer patients having active pustual, papular, and comedonal acne. There was on average a greater than 70% improvement in their acne following a series of three treatments administered a month apart.
  • FIG. 1 schematically illustrates a section of human tissue including dermal layers and underlying vasculature thereof.
  • FIG. 2 is a graph schematically illustrating absorptivity of hemoglobin and melanin as a function of wavelength in a wavelength region of the visible electromagnetic spectrum between 500 nanometers and 600 nanometers.
  • FIG. 3 schematically illustrates laser apparatus used for experimental treatment of erythematous papules in accordance with the method of the present invention.
  • the method of the present invention relies on using laser radiation to stimulate the skin's wound healing responses.
  • the laser radiation wavelength and the laser radiation fluence are selected such that the wound healing responses are stimulated without actually inflicting a wound.
  • the wound healing responses promote growth or production of dermal collagen.
  • wound here is meant to define an open wound, blister or any other effect which would be manifest in, or lead to, necrosis of tissue.
  • the dermis is composed of cellular and extracellular constituents that interact with one another to form a highly ordered, yet quite dynamic structure.
  • the major components of the extracellular matrix are collagen, elastic fibers, fibronectin, glycosaminoglycans, and proteoglycans.
  • the stimulated growth and remodeling of dermal extracellular matrix “bulks-up” the dermal tissue, and alters the milleau surrounding the hair follicle and sebaceous glands. This alters the anatomy of the follicle and the sebaceous gland unit causing a reduction in comedonal, papular and pustular acne.
  • the method may also be employed to treat other conditions that result in erythematous papules, such as rosacea.
  • the term erythematous papules is meant to include, but not be limited to, acne and rosacea.
  • the superficial vascular endothelium and the epidermal keratinocytes are stimulated by heating them with light that is well absorbed by both structures. This requires that the light be optimally absorbed in both melanin and in hemoglobin of the superficial vasculature.
  • FIG. 1 schematically illustrates a section of human skin including a region 10 generally defined as the epidermis and a region 12 generally defined as the dermis.
  • the epidermis 10 includes an outer layer (stratum corneium) 14 , and a lower (melanocyte) layer 16 including melanin pigment.
  • Some keratinocytes are heavily pigmented and contain melanosomes which feed melanin to the surrounding cells.
  • the epidermis is made up primarily of keratinocytes.
  • vasculature 18 has a superficial portion thereof comprising a plurality of capillary loops 20 .
  • absorption by melanin in melanocyte layer 16 and in capillary loops 20 of vasculature 18 preferentially heats a shallow region 20 immediately below layer 16 thereby heating the layer by conduction and providing the desired wound healing stimulus.
  • FIG. 2 graphically, schematically illustrates absorptivity of blood (curve A) and melanin (curve B) as a function of wavelength in a wavelength region between 500 nm and 600 nm in the visible electromagnetic spectrum.
  • absorptivity in haemoglobin is at or near a peak while absorption in melanin is also at a high level.
  • the high melansome absorptivity helps in maintaining the desired heating effect at the superficial level in skin being treated.
  • melanosome absorptivity is significantly less than at 525 nm and approaches equality with hemoglobin absorptivity. This is one reason why dye lasers are preferred in prior-art treatment of vascular disorders and the like. In such treatments, absorption of radiation by melanin could cause undesirable side effects such as blistering of skin as well as preventing penetration of the radiation to the lower lying vasculature where it is needed.
  • electromagnetic radiation preferably having a wavelength between about 525 and 550 nm, and having an appropriate pulse duration and intensity, is used to provide a selective, localized temperature increase in the superficial vasculature 20 and, intentionally and therapeutically, in melanocyte layer 16 .
  • the temperature rise should be sufficient to stimulate the release of cytokines and other growth factors without appreciably damaging any of the structures of the skin.
  • this temperature is less than about 70° C., but must, of course, be higher than normal body temperature.
  • the treatment radiation is preferably delivered by a laser.
  • a laser for providing radiation in the inventive treatment of erythematous papules is a frequency doubled Nd:YAG laser. Such a laser operates most efficiently by generating 1064 nm fundamental radiation and converting this radiation to 532 nm radiation by intracavity frequency doubling.
  • laser apparatus 30 used for experimental treatments in accordance with the present invention includes a Coherent VersaPulseV intracavity frequency-doubled Nd:YAG laser 32 including a touch screen control display 34 for controlling operating parameters of the laser.
  • Laser 32 delivers 532 nm radiation via a fiber-optic cable 36 to a handpiece 38 .
  • Handpiece 38 includes optics (not shown) which allow delivery of the 532 nm laser radiation focussed in a range of spot sizes. Spot sizes are selectively adjustable by rotating a control ring 40 .
  • a stand-off probe 42 attached to handpiece 38 contacts tissue 44 being treated to ensure that radiation is always delivered in the same spot size as the handpiece is moved to different locations on tissue 44 . It is also possible to employ a handpiece that delivers a collimated beam. This allows for a range of variation of working distance while still maintaining a selected beam size.
  • laser 22 was arranged to deliver a spot having a diameter of about 3 mm.
  • the pulse duration was about 2.0 ms.
  • An average fluence of 7.5 J/cm 2 was used to treat active acne lesions of volunteer patients. A total of 6 volunteer patients were treated.
  • Active acne lesions having a size larger that 3.0 mm were treated by applying single pulses at adjacent locations over the area without overlapping pulses. There was a high degree of patient satisfaction with the improvement of their appearance after only two treatments (one treatment per month). There was on average a greater than 70% improvement in the acne after three laser treatments. The judgement of improvement was made by the patients themselves.
  • test pulses were delivered to a selected test are of that patient's skin, in a range of increasing fluences, until a fluence level was reached which produced observable inflammation.
  • Each test pulse was fired on a different portion of the patient's skin. It was found that fluences higher than 12 J/cm 2 at a pulse length of 2 ms generally caused blistering, even on light-skinned patients. Accordingly, a fluence less than about 10 J/cm 2 in a pulse having a duration of about 2 ms or generally less than 10 ms is preferred. It should be noted here that this simple inflammation does not constitute a wound as that term is defined herein. Under no circumstances should the fluence be sufficient to cause coagulation of blood in the vasculature.
  • Inflammation is a very specific process and is not synonymous with irritation. It is emphasized, however, that it is not necessarily the inflammation in itself that is responsible for the dermal extracellular matrix deposition and corresponding improvements of the inventive treatment. Numerous inflammatory skin conditions, such as vasculitis, Sweet's syndrome and insect bites, occur without deposition of dermal extracellular matrix.
  • the experimental treatments were performed without resort to any skin cooling mechanisms such as contact cooling, cryogen spray cooling or the application of cooling gels to areas being treated. It is possible, however, that the method of the present invention may be made part of an integrated approach to the treatment of erythematous papules by combining the above-described radiation therapy with application of agents such as alpha-hydroxy acids, retinoids and growth factors that can positively impact the healing response.
  • a frequency doubled Nd:YAG laser can be arranged to deliver other wavelengths in the region between about 525 nm and 555 nm. These other wavelengths are about 531 nm, about 537 nm and about 539 nm which can be produced by frequency doubling fundamentally radiation at respectively about 1061 nm, about 1073 nm and about 1078 nm, the term about here meaning that the wavelengths are stated as rounded to the nearest nanometer.
  • 532 nm radiation may also be generated by a frequency-doubled Nd:YVO4 laser.
  • the use of any other laser providing radiation in the preferred, 525 nm to 550 nm range is not precluded in the present invention, nor is the use of any source of non-coherent light delivering radiation in this preferred wavelength range.
  • CW continuous wave
  • Scan speed (accordingly the dwell time of a beam in a particular area) can be selected, consistent with the beam size and power in the CW beam, such that the dwell time of radiation at a point being treated (due to the time taken for a beam of finite size to pass that point) delivers the appropriate fluence as indicated above.

Abstract

Methods for treating erythematous papules by irradiating skin with light having a wavelength between about 525 nanometers and 550 nanometers are provided.

Description

    INTRODUCTION
  • This patent application is a continuation-in-part of U.S. application Ser. No. 09/738,523 filed Dec. 15, 2000, which is herein incorporated by reference in its entirety.
  • FIELD OF THE INVENTION
  • The present invention relates in general to laser treatment of dermatological imperfections. The invention relates in particular to non-ablative laser treatment of erythematous papules such as acne and rosacea.
  • BACKGROUND OF THE INVENTION
  • The aesthetic treatment of abnormal dermatological conditions such as acne and rosacea has hitherto involved using topical treatments, physical methods of pore extraction, and oral antibiotics as well as oral retinoids. Prior-art treatments and investigations of treatments have been concentrated primarily on the use of antibiotics, steroid therapies, and low intensity blue light for photochemical therapy. Treatment of dermatological imperfections such as acne and rosacea has received relatively little investigative attention. While such imperfections may not be considered as aesthetically unpleasant or inconvenient, they are nonetheless dermatological imperfections. There is need for a method of improving the character of these imperfections without causing damage to peripheral tissue, and without leaving an open wound that must subsequently heal. Such a treatment could produce a long-lasting effect by altering the dermal extracellular matrix surrounding the follicles, which are the sites where acne takes place.
  • SUMMARY OF THE INVENTION
  • The present invention is directed to a method for treating erythematous papules as well as the skin between the papules. Acne-prone skin is erythematous not only in areas of active acne, but also in areas where acne has previously occurred, or where it is about to occur. In addition, acne lesions often have excess melanin pigment in the area where inflammation has caused deposition of excess epidermal melanin in the superficial dermis and in the area of the hair follicles. In one aspect, the method of the present invention comprises irradiating the skin to be treated with light (electromagnetic radiation) having a wavelength selected such that it is preferentially absorbed in a dermal region of the skin including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below the melanocyte layer. The light is delivered at a fluence sufficient that the preferential absorption thereof stimulates a wound healing response in the dermal region without causing a wound. The wound healing response promotes growth of dermal collagen, and other extracellular matrix and inflammatory compounds, in the area surrounding the hair follicles. This reorganization of dermal collagen affects the structure and function of sebaceous glands, altering their activity and reducing the incidence, severity and appearance of erythematous papules such as, but not limited to, rosacea, and both inflammatory and comedonal acne.
  • Preferably, the light has a wavelength between about 525 and 550 nanometers (nm). The light may be delivered in the form of pulses thereof or as a continuous beam swept or scanned over an area of skin being treated.
  • In experimental treatments in accordance with the present invention, pulsed electromagnetic radiation having a wavelength of 532 nm, delivered by a frequency-doubled Nd:YAG laser was arranged to deliver a spot having a diameter of about 3 millimeters (mm). The pulse duration was about 2.0 milliseconds (ms). An average fluence of 7.5 Joules per square centimeter (J/cm2) was used to treat 6 volunteer patients having active pustual, papular, and comedonal acne. There was on average a greater than 70% improvement in their acne following a series of three treatments administered a month apart.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings, which are incorporated in and constitute a part of the specification, schematically illustrate a preferred embodiment of the present invention, and together with the general description given above and the detailed description of the preferred embodiment given below, serve to explain the principles of the invention.
  • FIG. 1 schematically illustrates a section of human tissue including dermal layers and underlying vasculature thereof.
  • FIG. 2 is a graph schematically illustrating absorptivity of hemoglobin and melanin as a function of wavelength in a wavelength region of the visible electromagnetic spectrum between 500 nanometers and 600 nanometers.
  • FIG. 3 schematically illustrates laser apparatus used for experimental treatment of erythematous papules in accordance with the method of the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The method of the present invention relies on using laser radiation to stimulate the skin's wound healing responses. The laser radiation wavelength and the laser radiation fluence are selected such that the wound healing responses are stimulated without actually inflicting a wound. The wound healing responses promote growth or production of dermal collagen. The term “wound” here is meant to define an open wound, blister or any other effect which would be manifest in, or lead to, necrosis of tissue.
  • The biology of wound healing is a very complex process. Cytokines released by the vascular endothelial cells and epidermal keratinocytes are responsible for initiating the increased production of collagen. This takes place in a series of interrelated steps via the resident cells of the dermis. These elements lie in the uppermost regions of the skin. By selecting a wavelength of laser radiation in a range between about 525 and 550 nm, the wound healing response is concentrated close to these upper regions of the skin, and accordingly close to the location of imperfections being treated.
  • The dermis is composed of cellular and extracellular constituents that interact with one another to form a highly ordered, yet quite dynamic structure. Other than water, the major components of the extracellular matrix are collagen, elastic fibers, fibronectin, glycosaminoglycans, and proteoglycans. The stimulated growth and remodeling of dermal extracellular matrix “bulks-up” the dermal tissue, and alters the milleau surrounding the hair follicle and sebaceous glands. This alters the anatomy of the follicle and the sebaceous gland unit causing a reduction in comedonal, papular and pustular acne. The method may also be employed to treat other conditions that result in erythematous papules, such as rosacea. As such, the term erythematous papules is meant to include, but not be limited to, acne and rosacea.
  • The superficial vascular endothelium and the epidermal keratinocytes are stimulated by heating them with light that is well absorbed by both structures. This requires that the light be optimally absorbed in both melanin and in hemoglobin of the superficial vasculature.
  • FIG. 1 schematically illustrates a section of human skin including a region 10 generally defined as the epidermis and a region 12 generally defined as the dermis. The epidermis 10 includes an outer layer (stratum corneium) 14, and a lower (melanocyte) layer 16 including melanin pigment. Some keratinocytes are heavily pigmented and contain melanosomes which feed melanin to the surrounding cells. The epidermis is made up primarily of keratinocytes.
  • In the papillary, or upper dermis 12, vasculature 18 has a superficial portion thereof comprising a plurality of capillary loops 20. In the method of the present invention, absorption by melanin in melanocyte layer 16 and in capillary loops 20 of vasculature 18 preferentially heats a shallow region 20 immediately below layer 16 thereby heating the layer by conduction and providing the desired wound healing stimulus. It is believed, without being limited to a particular theory, that heating of keratincytes and the walls of the vessels of vasculature 18, in particular of the capillary loops 20 close to the epidermis 10, induces the secretion of cytokines that stimulate cells of the dermis 12 to produce the extracellular matrix and inflammatory compounds, in the area surrounding a hair follicle 24. This reorganization of dermal collagen affects the structure and function of sebaceous gland 26, altering their activity and reducing the incidence, severity and appearance of erythematous papules.
  • FIG. 2 graphically, schematically illustrates absorptivity of blood (curve A) and melanin (curve B) as a function of wavelength in a wavelength region between 500 nm and 600 nm in the visible electromagnetic spectrum. In the preferred wavelength region of 525 to 550 nanometers absorptivity in haemoglobin is at or near a peak while absorption in melanin is also at a high level. The high melansome absorptivity helps in maintaining the desired heating effect at the superficial level in skin being treated. By way of contrast, in the “yellow” wavelength region around 580 nm where dye lasers emit, melanosome absorptivity is significantly less than at 525 nm and approaches equality with hemoglobin absorptivity. This is one reason why dye lasers are preferred in prior-art treatment of vascular disorders and the like. In such treatments, absorption of radiation by melanin could cause undesirable side effects such as blistering of skin as well as preventing penetration of the radiation to the lower lying vasculature where it is needed.
  • In the inventive erythematous papule treatment method, electromagnetic radiation (light) preferably having a wavelength between about 525 and 550 nm, and having an appropriate pulse duration and intensity, is used to provide a selective, localized temperature increase in the superficial vasculature 20 and, intentionally and therapeutically, in melanocyte layer 16. The temperature rise should be sufficient to stimulate the release of cytokines and other growth factors without appreciably damaging any of the structures of the skin. Preferably, this temperature is less than about 70° C., but must, of course, be higher than normal body temperature. It is believed that at wavelengths increasingly shorter than 525 nm, as absorption becomes increasingly, proportionately higher in melanin than in hemoglobin, that sufficient heating of the target region cannot be obtained without overheating the melanocyte layer and causing blistering. At wavelengths increasingly longer than 550 nm, decreasing melanin absorption will allow penetration of radiation to depths in the vasculature at which it is less therapeutically effective, if at all.
  • The treatment radiation is preferably delivered by a laser. One suitable laser for providing radiation in the inventive treatment of erythematous papules is a frequency doubled Nd:YAG laser. Such a laser operates most efficiently by generating 1064 nm fundamental radiation and converting this radiation to 532 nm radiation by intracavity frequency doubling.
  • Referring now to FIG. 3, laser apparatus 30 used for experimental treatments in accordance with the present invention includes a Coherent VersaPulseV intracavity frequency-doubled Nd:YAG laser 32 including a touch screen control display 34 for controlling operating parameters of the laser. Laser 32 delivers 532 nm radiation via a fiber-optic cable 36 to a handpiece 38. Handpiece 38 includes optics (not shown) which allow delivery of the 532 nm laser radiation focussed in a range of spot sizes. Spot sizes are selectively adjustable by rotating a control ring 40. A stand-off probe 42 attached to handpiece 38 contacts tissue 44 being treated to ensure that radiation is always delivered in the same spot size as the handpiece is moved to different locations on tissue 44. It is also possible to employ a handpiece that delivers a collimated beam. This allows for a range of variation of working distance while still maintaining a selected beam size.
  • In experimental treatments in accordance with the present invention, laser 22 was arranged to deliver a spot having a diameter of about 3 mm. The pulse duration was about 2.0 ms. An average fluence of 7.5 J/cm2 was used to treat active acne lesions of volunteer patients. A total of 6 volunteer patients were treated.
  • Active acne lesions having a size larger that 3.0 mm were treated by applying single pulses at adjacent locations over the area without overlapping pulses. There was a high degree of patient satisfaction with the improvement of their appearance after only two treatments (one treatment per month). There was on average a greater than 70% improvement in the acne after three laser treatments. The judgement of improvement was made by the patients themselves.
  • In establishing a suitable fluence for treatment for each patient, test pulses were delivered to a selected test are of that patient's skin, in a range of increasing fluences, until a fluence level was reached which produced observable inflammation. Each test pulse was fired on a different portion of the patient's skin. It was found that fluences higher than 12 J/cm2 at a pulse length of 2 ms generally caused blistering, even on light-skinned patients. Accordingly, a fluence less than about 10 J/cm2 in a pulse having a duration of about 2 ms or generally less than 10 ms is preferred. It should be noted here that this simple inflammation does not constitute a wound as that term is defined herein. Under no circumstances should the fluence be sufficient to cause coagulation of blood in the vasculature.
  • Inflammation is a very specific process and is not synonymous with irritation. It is emphasized, however, that it is not necessarily the inflammation in itself that is responsible for the dermal extracellular matrix deposition and corresponding improvements of the inventive treatment. Numerous inflammatory skin conditions, such as vasculitis, Sweet's syndrome and insect bites, occur without deposition of dermal extracellular matrix.
  • The experimental treatments were performed without resort to any skin cooling mechanisms such as contact cooling, cryogen spray cooling or the application of cooling gels to areas being treated. It is possible, however, that the method of the present invention may be made part of an integrated approach to the treatment of erythematous papules by combining the above-described radiation therapy with application of agents such as alpha-hydroxy acids, retinoids and growth factors that can positively impact the healing response.
  • It should be noted, here, that the while above-described experimental treatments were conducted using the 532 nm wavelength of a frequency-doubled Nd:YAG this particular wavelength should not be construed as limiting the invention. By way of example using an appropriately wavelength selective resonator, a frequency doubled Nd:YAG laser can be arranged to deliver other wavelengths in the region between about 525 nm and 555 nm. These other wavelengths are about 531 nm, about 537 nm and about 539 nm which can be produced by frequency doubling fundamentally radiation at respectively about 1061 nm, about 1073 nm and about 1078 nm, the term about here meaning that the wavelengths are stated as rounded to the nearest nanometer. 532 nm radiation may also be generated by a frequency-doubled Nd:YVO4 laser. The use of any other laser providing radiation in the preferred, 525 nm to 550 nm range is not precluded in the present invention, nor is the use of any source of non-coherent light delivering radiation in this preferred wavelength range. It should also be noted that while single pulse delivery of radiation in experimental treatments is described, it is also possible to use continuous wave (CW) radiation and scan the radiation over tissue being treated. Scan speed (accordingly the dwell time of a beam in a particular area) can be selected, consistent with the beam size and power in the CW beam, such that the dwell time of radiation at a point being treated (due to the time taken for a beam of finite size to pass that point) delivers the appropriate fluence as indicated above.
  • The present invention is described above in terms of a preferred and other embodiments. The invention is not limited, however, by the embodiments described and depicted herein. Rather, the invention is limited only by the claims appended hereto.

Claims (33)

1. A method for treating erythematous papules in human skin, comprising: irradiating the skin with light having a wavelength between about 525 nanometers and 550 nanometers at a fluence level sufficient to promote a wound healing response in the skin but insufficient to cause a wound.
2. The method of claim 1 wherein the wavelength is about 532 nanometers.
3. The method of claim 1, wherein the fluence is less than about 20 J/cm2.
4. The method of claim 1 wherein the light is delivered in the form of one or more pulses.
5. The method of claim 4 wherein the one or more pulses each have a duration of about 10 milliseconds or less.
6. The method of claim 1, wherein the light is delivered as CW radiation and is scanned over an area of skin being treated.
7. The method of claim 1 wherein the light is coherent light delivered by a laser.
8. The method of claim 1, wherein the light is incoherent light.
9. The method of claim 1, wherein the erythematous papules comprise acne.
10. The method of claim 1, wherein the erythematous papules comprise rosacea.
11. The method of claim 1, wherein the light is absorbed preferentially in a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below the melanocyte layer, thereby heating the dermal region to a temperature higher than normal body temperature but less than about 70° C., to promote a wound healing response.
12. A method for treating acne in human skin, comprising:
irradiating the skin with light having a wavelength between about 525 nanometers and 550 nanometers such that a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below the melanocyte layer are heated to a temperature higher than normal body temperature but less than about 70° C., wherein heating stimulates production of dermal collagen in the dermal region, said dermal collagen production reduces incidence, severity or appearance of the acne.
13. The method of claim 12, wherein the wavelength is about 532 nanometers.
14. The method of claim 12, wherein the fluence is less than about 20 J/cm2.
15. The method of claim 12, wherein the light is delivered in the form of one or more individual pulses.
16. The method of claim 15, wherein the one or more pulses each have a duration of about 10 milliseconds or less.
17. The method of claim 12, wherein the light is delivered as CW radiation and is scanned over an area of skin being treated.
18. The method of claim 12, wherein the light is coherent light delivered by a laser.
19. The method of claim 12, the light is incoherent light.
20. A method for treating rosacea in human skin, comprising:
irradiating the skin with light having a wavelength between about 525 nanometers and 550 nanometers such that a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below said melanocyte layer are heated to a temperature less than about 70° C., thereby stimulating the production of dermal collagen in said dermal region, said dermal collagen production reducing the incidence, severity or appearance of said rosacea.
21. The method of claim 20, wherein the wavelength is about 532 nanometers.
22. The method of claim 20, wherein the fluence is less than about 20 J/cm2.
23. The method of claim 20, wherein the light is delivered in the form of one or more individual pulses.
24. The method of claim 23, wherein the one or more pulses each have a duration of about 10 milliseconds or less.
25. The method of claim 20, wherein the light is delivered as CW radiation and is scanned over an area of skin being treated.
26. The method of claim 20, wherein the light is coherent light delivered by a laser.
27. The method of claim 20, wherein the light is in coherent light.
28. A method for treating erythematous papules in human skin, comprising:
irradiating the skin with light having a wavelength selected so that it is preferentially absorbed in a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature below the melanocyte layer, the light being delivered at a fluence at which preferential absorption stimulates a wound healing response in the dermal region without causing a wound, said wound healing response promoting growth of dermal collagen in the dermal region, and reducing incidence, severity or appearance of the erythematous papules.
29. The method of claim 28, wherein preferential absorption heats the dermal region to a temperature higher than normal body temperature but less than about 70° C.
30. A method for treating acne in human skin, comprising:
irradiating the skin with light having a wavelength selected so that it is preferentially absorbed in a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature below the melanocyte layer, the light being delivered at a fluence at which preferential absorption stimulates a wound healing response in the dermal region without causing a wound, said wound healing response promoting growth of dermal collagen in the dermal region, and reducing incidence, severity or appearance of the acne.
31. The method of claim 30, wherein preferential absorption heats the dermal region to a temperature higher than normal body temperature but less than about 70° C.
32. A method for treating rosacea in human skin, comprising:
irradiating the skin with light having a wavelength selected so that it is preferentially absorbed in a dermal region including a melanocyte layer of the epidermis and a region of superficial vasculature immediately below the melanocyte layer, the light being delivered at a fluence at which preferential absorption stimulates a wound healing response in the dermal region without causing a wound, said wound healing response promoting growth of dermal collagen in the dermal region, reducing incidence, severity or appearance of the rosacea.
33. The method of claim 32, wherein preferential absorption heats the dermal region to a temperature higher than normal body temperature but less than about 70° C.
US10/913,075 2000-12-15 2004-08-06 Method of treating erythematous papules Abandoned US20050055071A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/913,075 US20050055071A1 (en) 2000-12-15 2004-08-06 Method of treating erythematous papules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/738,523 US6808532B2 (en) 2000-12-15 2000-12-15 Laser treatment for reducing wrinkles
US10/913,075 US20050055071A1 (en) 2000-12-15 2004-08-06 Method of treating erythematous papules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/738,523 Continuation-In-Part US6808532B2 (en) 2000-12-15 2000-12-15 Laser treatment for reducing wrinkles

Publications (1)

Publication Number Publication Date
US20050055071A1 true US20050055071A1 (en) 2005-03-10

Family

ID=24968376

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/738,523 Expired - Fee Related US6808532B2 (en) 2000-12-15 2000-12-15 Laser treatment for reducing wrinkles
US10/913,075 Abandoned US20050055071A1 (en) 2000-12-15 2004-08-06 Method of treating erythematous papules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/738,523 Expired - Fee Related US6808532B2 (en) 2000-12-15 2000-12-15 Laser treatment for reducing wrinkles

Country Status (2)

Country Link
US (2) US6808532B2 (en)
WO (1) WO2002064209A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070271714A1 (en) * 2006-03-17 2007-11-29 Light Dimensions, Inc. Light-based enhancing apparatuses and methods of use

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7204832B2 (en) * 1996-12-02 2007-04-17 Pálomar Medical Technologies, Inc. Cooling system for a photo cosmetic device
US8182473B2 (en) 1999-01-08 2012-05-22 Palomar Medical Technologies Cooling system for a photocosmetic device
US6517532B1 (en) 1997-05-15 2003-02-11 Palomar Medical Technologies, Inc. Light energy delivery head
EP0991372B1 (en) 1997-05-15 2004-08-04 Palomar Medical Technologies, Inc. Apparatus for dermatology treatment
US6104959A (en) 1997-07-31 2000-08-15 Microwave Medical Corp. Method and apparatus for treating subcutaneous histological features
AU3450799A (en) 1998-03-12 1999-09-27 Palomar Medical Technologies, Inc. System for electromagnetic radiation of the skin
US6888319B2 (en) * 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
AU2002361645A1 (en) * 2001-12-12 2003-07-09 Eric F. Bernstein Laser treatment for reduction of pore size
BR0312430A (en) 2002-06-19 2005-04-26 Palomar Medical Tech Inc Method and apparatus for treating skin and subcutaneous conditions
CN102698368A (en) 2002-10-23 2012-10-03 帕洛玛医疗技术公司 Phototreatment device for use with coolants and topical substances
ES2611284T3 (en) 2004-04-01 2017-05-08 The General Hospital Corporation Device for skin treatment and tissue remodeling
WO2006000873A2 (en) * 2004-06-21 2006-01-05 Kilolambda Technologies Ltd. Dermatological laser system
US7740018B1 (en) 2004-11-29 2010-06-22 Kamoey Marit Johanne Aoude Non-invasive laser treatment of large varices
US7856985B2 (en) 2005-04-22 2010-12-28 Cynosure, Inc. Method of treatment body tissue using a non-uniform laser beam
EP1924196A2 (en) 2005-09-15 2008-05-28 Palomar Medical Technologies, Inc. Skin optical characterization device
US8489067B2 (en) 2006-07-06 2013-07-16 Qualcomm Incorporated Methods and systems for distribution of a mobile wallet for a mobile device
US8510220B2 (en) 2006-07-06 2013-08-13 Qualcomm Incorporated Methods and systems for viewing aggregated payment obligations in a mobile environment
US8160959B2 (en) 2006-07-06 2012-04-17 Firethorn Mobile, Inc. Methods and systems for payment transactions in a mobile environment
US20080010204A1 (en) * 2006-07-06 2008-01-10 Firethorn Holdings, Llc Methods and Systems For Making a Payment Via a Paper Check in a Mobile Environment
US8467766B2 (en) 2006-07-06 2013-06-18 Qualcomm Incorporated Methods and systems for managing payment sources in a mobile environment
US8121945B2 (en) * 2006-07-06 2012-02-21 Firethorn Mobile, Inc. Methods and systems for payment method selection by a payee in a mobile environment
US9911114B2 (en) 2006-07-06 2018-03-06 Qualcomm Incorporated Methods and systems for making a payment via a stored value card in a mobile environment
US7586957B2 (en) 2006-08-02 2009-09-08 Cynosure, Inc Picosecond laser apparatus and methods for its operation and use
US20080082148A1 (en) * 2006-09-13 2008-04-03 Bernstein Eric F Laser treatment for skin tightening
US8688228B2 (en) 2007-04-19 2014-04-01 Miramar Labs, Inc. Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
WO2008131306A1 (en) 2007-04-19 2008-10-30 The Foundry, Inc. Systems and methods for creating an effect using microwave energy to specified tissue
WO2009075903A1 (en) 2007-04-19 2009-06-18 The Foundry, Inc. Systems and methods for creating an effect using microwave energy to specified tissue
WO2009075904A1 (en) 2007-04-19 2009-06-18 The Foundry, Inc. Methods, devices, and systems for non-invasive delivery of microwave therapy
US9149331B2 (en) 2007-04-19 2015-10-06 Miramar Labs, Inc. Methods and apparatus for reducing sweat production
ES2471971T3 (en) 2007-12-12 2014-06-27 Miramar Labs, Inc. System and apparatus for non-invasive treatment of tissue using microwave energy
EP2271276A4 (en) 2008-04-17 2013-01-23 Miramar Labs Inc Systems, apparatus, methods and procedures for the noninvasive treatment of tissue using microwave energy
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US9314301B2 (en) 2011-08-01 2016-04-19 Miramar Labs, Inc. Applicator and tissue interface module for dermatological device
TW201315506A (en) * 2011-10-13 2013-04-16 Forward Electronics Co Ltd Phototherapy device
EP2839552A4 (en) 2012-04-18 2015-12-30 Cynosure Inc Picosecond laser apparatus and methods for treating target tissues with same
WO2014160331A1 (en) * 2013-03-13 2014-10-02 Cynosure, Inc. Controlled photomechanical and photothermal tissue treatment in the picosecond regime
WO2014145707A2 (en) 2013-03-15 2014-09-18 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10779885B2 (en) 2013-07-24 2020-09-22 Miradry. Inc. Apparatus and methods for the treatment of tissue using microwave energy
EP3498211A1 (en) 2013-08-09 2019-06-19 The General Hospital Corporation Apparatus for treating dermal melasma
WO2016209834A1 (en) 2015-06-22 2016-12-29 Quantum Dynamics L.L.C. Device for providing body temperature regulation and/or therapeutic light directed to vasculature
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007079A1 (en) * 1997-10-17 2001-07-05 Chernoff W. Gregory Tissue treatment method
US6273883B1 (en) * 1996-04-09 2001-08-14 Cynosure, Inc. Alexandrite laser system for treatment of dermatological specimens
US20020169442A1 (en) * 1997-08-12 2002-11-14 Joseph Neev Device and a method for treating skin conditions
US6494900B1 (en) * 1997-01-06 2002-12-17 Norman Salansky Method for localized low energy photon therapy (LEPT)
US20030004501A1 (en) * 2001-03-08 2003-01-02 Wilkens Jan Hennrik Irradiation device and method for the treatment of acne and acne scars
US20030065313A1 (en) * 1999-07-29 2003-04-03 Koop Dale E. Thermal quenching of tissue
US6663659B2 (en) * 2000-01-13 2003-12-16 Mcdaniel David H. Method and apparatus for the photomodulation of living cells
US20040010299A1 (en) * 2002-04-16 2004-01-15 Seedling Enterprises, Llc Chemiluminescent light source using visible light for biotherapy
US20040073277A1 (en) * 2002-04-05 2004-04-15 Geronemus Roy G. High fluence rate activation of photosensitizers for dermatological applications
US20050055070A1 (en) * 2003-03-07 2005-03-10 Gareth Jones Method and device for treatment of skin conditions
US6913615B2 (en) * 2002-03-25 2005-07-05 Lumerx, Inc. Chemiluminescent treatment of acne

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97553A0 (en) * 1990-03-14 1992-06-21 Candela Laser Corp Apparatus and method of treating pigmented lesions using pulsed irradiation
US5611795A (en) * 1995-02-03 1997-03-18 Laser Industries, Ltd. Laser facial rejuvenation
US5964749A (en) 1995-09-15 1999-10-12 Esc Medical Systems Ltd. Method and apparatus for skin rejuvenation and wrinkle smoothing
US5871479A (en) 1996-11-07 1999-02-16 Cynosure, Inc. Alexandrite laser system for hair removal and method therefor
GB9618051D0 (en) 1996-08-29 1996-10-09 Sls Wales Ltd Wrinkle removal
US5810801A (en) * 1997-02-05 1998-09-22 Candela Corporation Method and apparatus for treating wrinkles in skin using radiation
EP0991372B1 (en) * 1997-05-15 2004-08-04 Palomar Medical Technologies, Inc. Apparatus for dermatology treatment
US6312450B1 (en) * 1997-05-20 2001-11-06 Natural Vision Center, Inc. System and method for improving the appearance of skin
US6110195A (en) * 1998-06-01 2000-08-29 Altralight, Inc. Method and apparatus for surgical and dermatological treatment by multi-wavelength laser light
US6077294A (en) 1998-06-11 2000-06-20 Cynosure, Inc. Method for non-invasive wrinkle removal and skin treatment
US6210426B1 (en) * 1999-01-15 2001-04-03 Cynosure Inc Optical radiation treatment for prevention of surgical scars

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273883B1 (en) * 1996-04-09 2001-08-14 Cynosure, Inc. Alexandrite laser system for treatment of dermatological specimens
US20020016587A1 (en) * 1996-04-09 2002-02-07 Cynosure, Inc. Laser system and method for treatment of biologic targets
US6494900B1 (en) * 1997-01-06 2002-12-17 Norman Salansky Method for localized low energy photon therapy (LEPT)
US20020169442A1 (en) * 1997-08-12 2002-11-14 Joseph Neev Device and a method for treating skin conditions
US20010007079A1 (en) * 1997-10-17 2001-07-05 Chernoff W. Gregory Tissue treatment method
US20030065313A1 (en) * 1999-07-29 2003-04-03 Koop Dale E. Thermal quenching of tissue
US6663659B2 (en) * 2000-01-13 2003-12-16 Mcdaniel David H. Method and apparatus for the photomodulation of living cells
US20030004501A1 (en) * 2001-03-08 2003-01-02 Wilkens Jan Hennrik Irradiation device and method for the treatment of acne and acne scars
US6913615B2 (en) * 2002-03-25 2005-07-05 Lumerx, Inc. Chemiluminescent treatment of acne
US20040073277A1 (en) * 2002-04-05 2004-04-15 Geronemus Roy G. High fluence rate activation of photosensitizers for dermatological applications
US20040010299A1 (en) * 2002-04-16 2004-01-15 Seedling Enterprises, Llc Chemiluminescent light source using visible light for biotherapy
US20050055070A1 (en) * 2003-03-07 2005-03-10 Gareth Jones Method and device for treatment of skin conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070271714A1 (en) * 2006-03-17 2007-11-29 Light Dimensions, Inc. Light-based enhancing apparatuses and methods of use

Also Published As

Publication number Publication date
US20020077678A1 (en) 2002-06-20
WO2002064209A1 (en) 2002-08-22
US6808532B2 (en) 2004-10-26

Similar Documents

Publication Publication Date Title
US20050055071A1 (en) Method of treating erythematous papules
US7033349B2 (en) Method of amplifying a beneficial selective skin response to light energy
US6702838B1 (en) Method of treating hypotrophic scars enlarged pores
US8323253B2 (en) Method and device for tightening tissue using electromagnetic radiation
US7060061B2 (en) Method and apparatus for the selective targeting of lipid-rich tissues
US5707403A (en) Method for the laser treatment of subsurface blood vessels
US20120029394A1 (en) Ultrasound Assisted Laser Skin and Tissue Treatment
US20080294150A1 (en) Photoselective Islets In Skin And Other Tissues
US20020045891A1 (en) Wrinkle reduction
US20100023003A1 (en) Skin rejuvination resurfacing device and method of use
JP2002537940A (en) Reduction of skin wrinkles using pulsed light
US20080234669A1 (en) Method and device for treating skin by superficial coagulation
KR20210023643A (en) Laser system for multiple beam tissue therapy
Sawcer et al. Lasers and adjunctive treatments for facial scars: a review
KR20230133840A (en) A cosmetic laser device that performs treatment by irradiating a variable pulse laser beam onto the human skin being treated.
US20190351253A1 (en) Apparatus and method for tissue regeneration
Sadick Electro-optical synergy in aesthetic medicine: novel technology, multiple applications
Boechat et al. Lasers, Lights, and Related Technologies in Cosmetic Dermatology
Lanigan Lasers in dermatology
Alhallak et al. Scar Revision
Lee et al. Ablative Lasers and Fractional Lasers
Michel Flashlamp pumped dye laser (585 nm, low fluence) for aesthetic and medical indications: Own experience/results and review of literature
Nabatian et al. Nonablative Lasers
Willey et al. Broadband Light and Laser
Bernstein et al. Non-ablative wrinkle reduction with the Versapulse laser system

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION